Last updated: 2026-09-05 05:54:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Kiora Pharmaceuticals, Inc. (KPRX) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $2.59, with a market capitalization of $11.46M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1.76 to $2.95. This page covers its latest market performance, valuation, price trends and company information.
$11.46M | |
$2.57 | |
$730.80 | |
$1.76 | |
$2.55 | |
4.39K | |
-- | |
-- | |
$2.95 | |
$1.76 | |
-- | |
-- |
Kiora Pharmaceuticals, Inc. (KPRX) last closed at $2.55 as of 2026-09-04 20:11:00, unchanged from the previous close of $2.55.
During the latest regular trading session, KPRX traded between $1.76 and $730.80, with a volume of 4.39K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Kiora Pharmaceuticals, Inc. (KPRX) moved from $2.52 to $2.59, representing a gain of 2.58% ($0.06).
The stock traded between $2.52 and $2.63 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 8.22 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 69.2%
KPRX is currently trading at $2.59, placing it 69.2% of the way from its 52-week low of $1.76 to its 52-week high of $2.95. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 13 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kiora Pharmaceuticals, Inc. (KPRX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.